IRCT20201110049334N1 IRCT 2021-01-30 Iran University of Medical Sciences Evaluation of estrogen therapy on the height of children with chronic kidney disease Evaluation of estrogen therapy on final height of short girls with chronic kidney disease (CKD) and delayed puberty 2014-03-21 anticipated 75 Complete https://irct.ir/trial/53097 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Short stature. Intervention 1: ّFirst intervention group: In this group, patients (N = 25) receive injection of growth hormone (Genotropin manufactured by Pfizer, US) from the beginning of short stature, at the rate of 0.05 mg/kg, once a day for 4-6 years and oral Estrogen (Ethinyl Estradiol, manufactured by Aburaihan, Iran) from the age of 11at the rate of 5 µg ( it will double every 3 to 6 months until to reach a dose of 30 µg) once a day and continues until the age of 16. Intervention 2: Second intervention group: In this group, patients (N = 25) receive injection of growth hormone (Genotropin manufactured by Pfizer, US) from the beginning of short stature, at the rate of 0.05 mg/kg, once a day for 4-6 years and oral Estrogen (Ethinyl Estradiol, manufactured by Aburaihan, Iran) from the age of 13 at the rate of 5 µg ( it will double every 3 to 6 months until to reach a dose of 30 µg) once a day and continues until the age of 16. Intervention 3: Control group: in this group patients (N = 25) do not receive growth hormone and estrogen until the age of 15 and are the same with both intervention groups in terms of age, sex, average parental height and stage of chronic kidney disease (There is no intervention in this group). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information